The Oregon Cancer Center (OCC), a matrix Clinical Cancer Center at Oregon Health Science University (OHSU) with 173 members, was awarded a CCSG (P30) two years ago. Since that time, the Center has been assigned 33,000 square feet of new space for its headquarters (11,000 square feet) and a new basic research building (22,000 square feet). Having focused on strengthening our clinical research infrastructure, we have successfully recruited senior leaders in clinical cancer research, two of whom are now principal investigators of multi- institutional study groups and serve on the Leadership Council of the Center. In the past two years of CCSG support, our investigators- institutional therapeutic clinical trials have increased fourfold, we are now ranked fourth in accruals to SWOG studies, and we have tripled CCG accruals. Our experimental Therapeutics program has focused directly on transplantation and cancer immunology, in part responding to criticisms in the prior review and input from the external advisory team. Now known is the Transplantation/Immunology Program, this group focuses on immunological tolerance in transplantation and cancer immunology. Because of the cohesiveness of this smaller, more focused group this program has the highest frequency of inter- and intra-programmatic publications in our Center. In cancer control, we have recruited seasoned investigators to the Center and have reached a critical mass in four focus areas driving support of this program's investigator-initiated research portfolio from $300,000 annually to more than $5 million annually in two years. In the past three years we have recruited 42 new members, and, in the next five years, we will recruit no fewer than 27 more in collaboration with 10 departments and institutes. The mission of our Center is to support research designed to identify molecular defects in neoplastic cells and to exploit such knowledge to develop more effective strategies for diagnosis, treatment, prevention, and control of malignant diseases. Translational research projects have increased in all five of the programs, and. in the past two years, some of our best scientific research projects have already moved into Phase I clinical trials.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
3P30CA069533-04S1
Application #
6354359
Study Section
Subcommittee G - Education (NCI)
Program Officer
Ciolino, Henry P
Project Start
1997-08-01
Project End
2005-05-31
Budget Start
2000-09-30
Budget End
2001-05-31
Support Year
4
Fiscal Year
2000
Total Cost
$180,694
Indirect Cost
Name
Oregon Health and Science University
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
009584210
City
Portland
State
OR
Country
United States
Zip Code
97239
Kurtz, Stephen E; Eide, Christopher A; Kaempf, Andy et al. (2018) Dual inhibition of JAK1/2 kinases and BCL2: a promising therapeutic strategy for acute myeloid leukemia. Leukemia 32:2025-2028
Sehrawat, Archana; Gao, Lina; Wang, Yuliang et al. (2018) LSD1 activates a lethal prostate cancer gene network independently of its demethylase function. Proc Natl Acad Sci U S A 115:E4179-E4188
Watson, Spencer S; Dane, Mark; Chin, Koei et al. (2018) Microenvironment-Mediated Mechanisms of Resistance to HER2 Inhibitors Differ between HER2+ Breast Cancer Subtypes. Cell Syst 6:329-342.e6
Li, Bingbing X; Chen, Jingjin; Chao, Bo et al. (2018) Anticancer Pyrroloquinazoline LBL1 Targets Nuclear Lamins. ACS Chem Biol 13:1380-1387
Hulett, Tyler W; Jensen, Shawn M; Wilmarth, Phillip A et al. (2018) Coordinated responses to individual tumor antigens by IgG antibody and CD8+ T cells following cancer vaccination. J Immunother Cancer 6:27
Vranka, Janice A; Staverosky, Julia A; Reddy, Ashok P et al. (2018) Biomechanical Rigidity and Quantitative Proteomics Analysis of Segmental Regions of the Trabecular Meshwork at Physiologic and Elevated Pressures. Invest Ophthalmol Vis Sci 59:246-259
Lane, Ryan S; Lund, Amanda W (2018) Non-hematopoietic Control of Peripheral Tissue T Cell Responses: Implications for Solid Tumors. Front Immunol 9:2662
Tyner, Jeffrey W; Tognon, Cristina E; Bottomly, Daniel et al. (2018) Functional genomic landscape of acute myeloid leukaemia. Nature 562:526-531
Risom, Tyler; Langer, Ellen M; Chapman, Margaret P et al. (2018) Differentiation-state plasticity is a targetable resistance mechanism in basal-like breast cancer. Nat Commun 9:3815
Minnier, Jessica; Pennock, Nathan D; Guo, Qiuchen et al. (2018) RNA-Seq and Expression Arrays: Selection Guidelines for Genome-Wide Expression Profiling. Methods Mol Biol 1783:7-33

Showing the most recent 10 out of 277 publications